DFDaniel Fakhry-Darian

Daniel Fakhry-Darian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Fakhry-Darian has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Translation of PET radiotracers for cancer imaging: recommendations from the National Cancer Imaging Translational Accelerator (NCITA) consensus meeting

    by Martina A. McAteer, Daniel R. McGowan, Gary J. R. Cook, Hing Y. Leung, Tony Ng, James P. B. O’connor, Luigi Aloj, Anna Barnes, Phil J. Blower, Kevin M. Brindle, et al.

    Background: The clinical translation of positron emission tomography (PET) radiotracers for cancer management presents complex challenges. We have developed consensus-based recommendations for preclinical and clinical assessment of novel and established radiotracers, applied to image different cancer types, to improve the standardisation of translational methodologies and accelerate clinical implementation. Methods: A consensus process was developed using the RAND/UCLA Appropriateness Method (RAM) to gather insights from a multidisciplinary panel of 38 key stakeholders on the appropriateness of preclinical and clinical methodologies and stakeholder engagement for PET radiotracer translation. Panellists independently completed a consensus survey of 57 questions, rating each on a 9-point Likert scale. Subsequently, panellists attended a consensus meeting to discuss survey outcomes and readjust scores independently if desired. Survey items with median scores ≥ 7 were considered ‘required/appropriate’, ≤ 3 ‘not required/inappropriate’, and 4–6 indicated ‘uncertainty remained’. Consensus was determined as ~ 70% participant agreement on whether the item was ‘required/appropriate’ or ‘not required/not appropriate’. Results: Consensus was achieved for 38 of 57 (67%) survey questions related to preclinical and clinical methodologies, and stakeholder engagement. For evaluating established radiotracers in new cancer types, in vitro and preclinical studies were considered unnecessary, clinical pharmacokinetic studies were considered appropriate, and clinical dosimetry and biodistribution studies were considered unnecessary, if sufficient previous data existed. There was ‘agreement without consensus’ that clinical repeatability and reproducibility studies are required while ‘uncertainty remained’ regarding the need for comparison studies. For novel radiotracers, in vitro and preclinical studies, such as dosimetry and/or biodistribution studies and tumour histological assessment were considered appropriate, as well as comprehensive clinical validation. Conversely, preclinical reproducibility studies were considered unnecessary and ‘uncertainties remained’ regarding preclinical pharmacokinetic and repeatability evaluation. Other consensus areas included standardisation of clinical study protocols, streamlined regulatory frameworks and patient and public involvement. While a centralised UK clinical imaging research infrastructure and open access federated data repository were considered necessary, there was ‘agreement without consensus’ regarding the requirement for a centralised UK preclinical imaging infrastructure. Conclusions: We provide consensus-based recommendations, emphasising streamlined methodologies and regulatory frameworks, together with active stakeholder engagement, for improving PET radiotracer standardisation, reproducibility and clinical implementation in oncology.


  • Optimisation and usefulness of quantitative analysis of 18F-florbetapir PET

    by Daniel Fakhry-Darian, Neva Hiten Patel, Sairah Khan, Tara Barwick, William Svensson, Sameer Khan, Richard J Perry, Paresh Malhotra, Christopher J Carswell, Kuldip S Nijran, et al.

    Objectives: This study investigates the usefulness of quantitative SUVR thresholds on sub types of typical (type A) and atypical (non-type A) positive (Aβ+) and negative (Aβ-) 18F-florbetapir scans and aims to optimise the thresholds. Methods: Clinical 18F-florbetapir scans (n = 100) were categorised by sub type and visual reads were performed independently by three trained readers. Inter-reader agreement and reader-to-reference agreement were measured. Optimal SUVR thresholds were derived by ROC analysis and were compared with thresholds derived from a healthy control group and values from published literature. Results: Sub type division of 18F-florbetapir PET scans improves accuracy and agreement of visual reads for type A: accuracy 90%, 96% and 70% and agreement κ > 0.7, κ ≥ 0.85 and −0.1 < κ < 0.9 for all data, type A and non-type A respectively. Sub type division also improves quantitative classification accuracy of type A: optimum mcSUVR thresholds were found to be 1.32, 1.18 and 1.48 with accuracy 86%, 92% and 76% for all data, type A and non-type A respectively. Conclusions: Aβ+/Aβ- mcSUVR threshold of 1.18 is suitable for classification of type A studies (sensitivity = 97%, specificity = 88%). Region-wise SUVR thresholds may improve classification accuracy in non-type A studies. Amyloid PET scans should be divided by sub type before quantification. Advances in knowledge: We have derived and validated mcSUVR thresholds for Aβ+/Aβ- 18F-florbetapir studies. This work demonstrates that division into sub types improves reader accuracy and agreement and quantification accuracy in scans with typical presentation and highlights the atypical presentations not suited to global SUVR quantification.


  • Quantitative evaluation of beta-amyloid brain PET imaging in dementia: a comparison between two commercial software packages and the clinical report

    by Sorcha Curry, Neva Patel, Daniel Fakhry-Darian, Sairah Khan, Richard J Perry, Paresh A Malhotra, Kuldip S Nijran, Zarni Win

    Objective: To compare commercially available image analysis tools Hermes BRASS and Siemens Syngo.VIA with clinical assessment in 18F-Florbetapir PET scans Methods: 225 scans were reported by clinicians and quantified using two software packages. Scans were classified into Type A (typical features) or non-Type A (atypical features) for both positive and negative scans. For BRASS, scans with z-score ≥ 2 in 2 ≥ region of interest were classed positive. For Syngo.VIA a positive scan was indicated when mean cortical standardized uptake value ratio (mcSUVR) ≥ 1.17. Results: 81% scans were Type A, and 19% scans were non-Type A. The sensitivity of BRASS and Syngo.VIA for Type A scans was 98.8 and 96.3%, specificity was 73 and 92%, respectively. Sensitivity for non-Type A scans was 95.8 and 79.2%, specificity was 36.8 and 57.9%, respectively. A third threshold of identifiable levels of plaque (1.08 ≤ mcSUVR ≤ 1.17) was recommended for Syngo.VIA to increase detection of false negative scans. The false positive rate of BRASS significantly decreased when an alternative positive threshold value of mcSUVR ≥ 1.18. Introduction of alternative criteria did not improve prediction outcome for non-Type A scans. More complex solutions are recommended. Conclusion: Hermes criteria for a positive scan leads to a high sensitivity but a low specificity. Siemens Syngo.VIA criteria gives a high sensitivity and specificity and agrees better with the clinical report. Alternative thresholds and classifications may help to improve agreement with the clinical report. Advances in knowledge: Software packages may assist with clinical reporting of more difficult to interpret cases that require a more experienced read.


  • Improving Lung Lesion Detection in Low Dose Positron Emission Tomography Images Using Machine Learning

    by Yinghwey Nai, Joshua D. Schaefferkoetter, Daniel Fakhry-Darian, Maurizio Conti, Xinmei Shi, David W. Townsend, Arvind K. Sinha, Ivan Tham, Daniel C. Alexander, Anthonin Reilhac

    Lung cancer suffers from poor prognosis, leading to high death rates. Combined PET/CT improves lung lesion detection but requires low dose protocols for frequent disease screening and monitoring. In this study, we investigate the feasibility of using machine learning to improve low dose PET images to standard dose, high-quality images for better lesion detection at low dose PET scans. We employ image quality transfer (IQT), which is a machine learning algorithm that uses patch-regression to map parameters from low to high-quality images e.g. enhancing resolution or information content. We acquired 20 standard dose PET images and simulated low dose PET images with 9 different count levels from the standard dose PET images. For each count levels, 10 pairs of standard dose PET images with one simulated low dose PET images were used to train linear, single non-linear regression tree, and random regression-forest models for IQT. The models were then used to estimate standard dose images from low dose images for each count levels for 10 different subjects. Improvement in image quality and lesion detection could be observed in the images estimated from the low dose images using IQT. Among the models employed, the regression tree model produced the best estimates of standard dose PET images. An average bias of less than 20% in SUV mean of 25 lesions in the estimated images from the standard dose PET images can be obtained down to 7.5 × 10 6 counts. Overall, despite the increase in bias, the improvement in image quality shows the potential of IQT in improving the accuracy in lesion detection.